Research guide · Published July 23, 2026 · Sources checked July 23, 2026
KPV, PepT1, and NF-kappaB: what intestinal inflammation models show
KPV is the tripeptide Lys-Pro-Val and corresponds to residues 11–13 at the carboxyl terminus of alpha-melanocyte-stimulating hormone. Its short sequence does not make all proposed mechanisms or delivery methods interchangeable.
Short answer
Selected studies reported that KPV can be transported through peptide transporter 1 (PepT1) in experimental systems and can alter NF-kappaB-, MAP-kinase-, cytokine-, and histology-associated measurements in cultured cells and mouse intestinal-inflammation models. These findings do not establish a human treatment effect.
Evidence boundary: The cited studies do not establish clinical safety, efficacy, dosing, delivery, or suitability for human inflammatory bowel disease or any other condition. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Research question | What was measured | Important limit |
|---|---|---|
| Is KPV simply alpha-MSH? | KPV is the Lys-Pro-Val carboxyl-terminal fragment of alpha-MSH | A tripeptide fragment is not the full parent peptide |
| How was cellular entry studied? | PepT1 uptake in epithelial and immune-cell systems | Transporter expression varies by cell type and inflammatory state |
| Which signaling endpoints changed? | NF-kappaB, MAP-kinase, chemokine, and cytokine-associated measurements | A signaling change is not proof of organism-level efficacy |
| Which animal models were used? | DSS, TNBS, transfer-colitis, and colitis-associated-cancer mouse systems | These are distinct induced models, not interchangeable human diseases |
How to interpret the comparison
The PepT1 work gives KPV research a testable transport hypothesis, while other experiments suggest melanocortin-receptor-independent effects in selected contexts. Mechanistic claims should name the cell type, transporter or receptor status, and assay.
DSS, TNBS, and immune-cell-transfer models produce intestinal injury through different experimental mechanisms. Consistency across models can strengthen a preclinical signal, but it does not remove the gap between induced mouse inflammation and clinical disease.
Primary sources
- Dalmasso et al., Gastroenterology (2008) — Cell and mouse studies of PepT1-mediated KPV uptake, inflammatory signaling, and DSS- and TNBS-colitis endpoints. DOI: 10.1053/j.gastro.2007.10.026
- Kannengiesser et al., Inflammatory Bowel Diseases (2008) — KPV experiments in two mouse intestinal-inflammation models, including mice with nonfunctional MC1R. DOI: 10.1002/ibd.20334
- Viennois et al., Cellular and Molecular Gastroenterology and Hepatology (2016) — PepT1 and KPV experiments in a mouse model of colitis-associated cancer. DOI: 10.1016/j.jcmgh.2016.01.006
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.